Tumor Suppressor Role and Clinical Significance of the FEV Gene in Prostate Cancer

Table 3

Prognostic value of FEV expression in overall survival using a Cox proportional hazards model.

Parameters	Univariate analysis		Multivariate analysis
	DASL dataset ()
Age (<66 vs. ≥66)	1.265 (0.794-2.015)	0.323
Preoperative PSA (<4 vs. ≥4)	1.954 (0.776-4.921)	0.155
Pathological tumor stage (<T3A vs. ≥T3A)	2.336 (1.479-3.785)	<0.001	1.344 (0.817-2.210)	0.244
Gleason score (<7 vs. =7 vs. ≥7)	2.978 (2.114-4.195)	<0.001	2.539 (1.764-3.655)	<0.001
FEV (low vs. high)	0.466 (0.294-0.738)	0.001	0.606 (0.817-2.210)	0.038
TCGA dataset ()
Age (<66 vs. ≥66)	1.208 (0.676-2.157	0.524
Pathological tumor stage (<T3A vs. ≥T3A)	3.362 (1.680-6.726)	0.001	2.698 (1.340-5.431)	0.005
Gleason score (<7 vs. =7 vs. ≥7)	3.440 (2.018-5.863)	<0.001	3.025 (1.709-5.354)	<0.001
FEV (low vs. high)	0.616 (0.362-1.050)	0.075	0.811 (0.456-1.442)	0.475